Rationale and design of DUAL study: Doxycycline to Upgrade response in light chain (AL) amyloidosis (DUAL): A phase 2 pilot study of a two-pronged approach of prolonged doxycycline with plasma cell-directed therapy in the treatment of AL amyloidosis

Light chain (AL) amyloidosis is a plasma cell neoplasm associated with insoluble fibril deposition from clonal immunoglobulin chains systemically. The disease is associated with high early mortality and morbidity owing to advanced organ deposition as well as lack of proven de-fibrillogenic therapies...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Contemp Clin Trials Commun
Hlavní autoři: D'Souza, Anita, Flynn, Kathryn, Chhabra, Saurabh, Dhakal, Binod, Hamadani, Mehdi, Jacobsen, Kirsten, Pasquini, Marcelo, Weihrauch, Dorothee, Hari, Parameswaran
Médium: Artigo
Jazyk:Inglês
Vydáno: Elsevier 2017
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5898504/
https://ncbi.nlm.nih.gov/pubmed/29696194
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.conctc.2017.08.012
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky